Overview
WuXi AppTec is a global contract research, development and manufacturing organization (CRDMO) serving the pharmaceutical and life-sciences industries. Its integrated services support drug discovery, development, testing and manufacturing, across chemistry, testing and biology operations.[1][2][3]
The company serves customers in more than 30 countries and has operations across Asia, Europe and North America. Its stated vision is “every drug can be made and every disease can be treated,” reflecting its role in helping customers develop medicines.[4][5][6]
WuXi AppTec’s predecessor was established in 2000. In 2025, the company reported total revenue of RMB 45.456 billion; its official overview describes a global workforce of more than 35,000 employees.[7][8][9] [1][2][3][4][5][6][7][8][9][9][4][5]
Products & services
WuXi AppTec provides R&D services rather than a conventional range of finished medicines. Its WuXi Chemistry platform supports drug development from discovery through preclinical and clinical stages to commercial manufacturing, including small molecules, oligonucleotides, peptides and related chemistry conjugates. Chemistry services include API development, process R&D, manufacturing and formulation for chemical drugs.[2][10][11] WuXi Testing combines CMC, pharmacology, DMPK, toxicology and bioanalysis capabilities to support programs from discovery through IND and beyond.[2][12]
WuXi Biology supports target discovery and validation, candidate selection and optimization, and progression toward clinical development. Its capabilities include target knockdown or overexpression, knockout and knock-in models, functional and rescue studies, and biochemical, cell-based, pathway-based phenotypic and high-content assays.[2][13][14] In FY2025, continuing-operations revenue was RMB36,465.847 million for Chemistry (about 84.0%), RMB4,041.701 million for Testing (9.3%), RMB2,677.175 million for Biology (6.2%) and RMB236.101 million for Other (0.5%), out of RMB43,420.824 million. These percentages are calculated from reported segment revenue and describe revenue mix, not a separate measure of product sales.[8] [2][8][8][8][8][8][8][8][10][11][12][13][14]
Geographic presence
In 2025, WuXi AppTec reported regional revenue of RMB31.25 billion from the US (72%), RMB5.47 billion from China (13%), RMB4.82 billion from Europe (11%), and RMB1.88 billion from Japan, Korea and other markets (4%).[15] The figures are from the company’s “Diversified Revenue Streams by Region” presentation; the materials do not specify a more precise basis for regional attribution.[16]
The company describes its operations as spanning Asia, Europe and North America.[17] Its disclosed locations include multiple Chinese cities—among them Shanghai, Tianjin, Wuhan, Chengdu, Nantong, Changzhou, Taixing, Wuxi and Changshu—and US sites including Middletown, Delaware; Cranbury, New Jersey; San Diego, California; and Natick, Massachusetts.[18][5] In Europe, the company identifies Munich, Germany, and Couvet, Switzerland, as locations in its footprint.[19] The 2025 annual report states that 20 main sites were ISO/IEC 27001-certified, including all main sites in China.[20] [15][15][15][15][17][20][16][18][5][19]
Business segments
WuXi AppTec’s 2025 continuing-operations segments are WuXi Chemistry, WuXi Testing, WuXi Biology and Others [3]. WuXi Chemistry provides chemistry drug-development services from discovery through preclinical and clinical development to commercial manufacturing, across synthetic molecular modalities, with formulation support. WuXi Testing provides drug-R&D testing across CMC, pharmacology, DMPK, toxicology and bioanalysis. WuXi Biology supports research and testing from target discovery through candidate selection and optimization and into the clinic [2]. Others comprises non-core business, administrative-service income, and sales of raw and scrap materials [2].
Based on 2025 revenue from continuing operations, WuXi Chemistry contributed RMB36,465,847 thousand (about 84.0%), WuXi Testing RMB4,041,701 thousand (about 9.3%), WuXi Biology RMB2,677,175 thousand (about 6.2%), and Others RMB236,101 thousand (about 0.5%), out of RMB43,420,824 thousand [8]. Percentages are approximate and calculated using the continuing-operations subtotal. [3][2][8][8][8][8][8]
Company history
WuXi AppTec’s predecessor was established in China in December 2000, initially focusing on synthetic chemistry services. It expanded into process development in 2003, R&D manufacturing in 2004, bioanalytical services in 2005, and toxicology and formulation in 2007.[21][22] The company listed on the New York Stock Exchange in 2007 and acquired U.S.-based AppTec in 2008, broadening its capabilities. It completed a going-private transaction and delisted from the NYSE in December 2015.[23][24]
In 2016, WuXi AppTec acquired German drug-discovery company Crelux.[25] Its biologics subsidiary, WuXi Biologics, listed in Hong Kong in 2017; WuXi AppTec returned to public markets with a Shanghai listing in May 2018 and a Hong Kong listing in December 2018.[26][27]
The company broke ground on a research and manufacturing site in Singapore in 2024.[28] In 2025, it completed sales of WuXi Clinical and WuXi MedKey and disposed of its WuXi ATU business and part of WuXi Testing; executive director and vice-chairman Edward Hu retired from those roles effective July 31.[29][30][31] [21][23][29][30][31][22][24][25][26][27][28]
Sources
- WUXI APPTEC CO LTD-A — Full financial report (2025 Y)
- www.wuxiapptec.com[4]
- www.wuxiapptec.com[5]
- www.wuxiapptec.com[9]
- chemistry.wuxiapptec.com[10]
- chemistry.wuxiapptec.com[11]
- www.wuxiapptec.com[12]
- wuxibiology.com[13]
- wuxibiology.com[14]
- WUXI APPTEC CO LTD-A — Presentation (2025 Y)[15]
- www.wuxiapptec.com[16]
- chemistry.wuxiapptec.com[18]
- wxpress.wuxiapptec.com[19]
- www.wuxiapptec.com[22]
- WUXI APPTEC CO LTD-A — Full financial report (2024 Y)[23]
- www.wuxiapptec.com[24]
- www.wuxiapptec.com[25]
- www.hkexnews.hk[26]
- www1.hkexnews.hk[27]
- www.wuxiapptec.com[28]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore WUXI APPTEC CO LTD-A in Finbar ↗